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Nonalcoholic fatty liver disease (NAFLD) is the fastest growing cause of chronic liver disease worldwide. Although only a small proportion of NAFLD patients will progress to end stage liver disease and death, the clinical burden of NAFLD is substantial due the sheer number of individuals affected worldwide. In fact, recent estimates suggest that 25% of the world have NAFLD, that is now one of the leading causes of cirrhosis and indications for liver transplantation. Although liver related mortality is common, the most common cause of death for those with NAFLD is related to cardiovascular diseases, followed by extra-hepatic cancers. There is a huge interindividual variability in liver disease susceptibility. The severity of metabolic alterations is the main risk factor for progressive NAFLD, but qualitative components of the diet, physical activity, and genetic factors play also an important role. In particular, common variants in Patatin-like phospholipase domain-containing 3 (PNPLA3), Transmembrane 6 superfamily member 2 (TM6SF2), Membrane bound O-acyl transferase 7 (MBOAT7) and Glucokinase regulator (GCKR) have been shown to contribute to the full spectrum of NAFLD pathology. In those at risk for potentially progressive form of NAFLD or non-alcoholic steatohepatitis or those with hepatic fibrosis, additional assessments must be undertaken. 







The acronym NAFLD (Non-alcoholic fatty liver disease) defines a spectrum of clinico-pathologic liver diseases that ranges from non-alcoholic fatty liver (NAFL or simple steatosis) to non-alcoholic steatohepatitis (NASH) and to cirrhosis, and its complications1. NAFLD clusters with obesity, T2DM and is commonly considered the hepatic manifestation of the metabolic syndrome (MS), reflecting shared pathogenic factors. The pathogenesis of the transition from simple steatosis to progressive disease is still not completely understood, and likely multifactorial1. NAFLD is rapidly becoming the leading cause of liver disease worldwide and among the top causes of cirrhosis and hepatocellular carcinoma (HCC). Currently, 25% of the general population all over the world is thought to have NAFLD, with the highest prevalence being reported from the Middle East and South America (31.79% and 30.45%, respectively) and the lowest from Africa (13.48%)2. Among patients with T2DM, the prevalence of NAFLD is higher at 57.80%3. Furthermore, among the morbidly obese, NAFLD prevalence can be as high as 95%4.
Since diagnosis of NASH is based on histology, true prevalence rates for NASH are uncertain. Estimated prevalence rates for NASH in the general population range from 1.5% to 6.45%2. The highest rates for NASH are found in diabetic patients (65.26%, with 15.05% of these patients having advanced fibrosis ≥ F3)3, and in morbid obese subjects (20-50% with 10% having advanced fibrosis)4. According to recent global modelling analyses based on changes in adult obesity and T2DM the prevalence of NAFLD is set to grow exponentially over the next decade5. 

Natural History of NAFLD
A diagnosis of NAFLD is associated with an increased mortality rate, with the three top causes of death being, in order, cardiovascular disease, extra-hepatic cancer and liver disease6. On the other hand, in patients with NASH and advanced fibrosis liver-related mortality predominates. Data about the natural history of NAFLD mainly come from tertiary centers: histologic cohorts with mortality data or repeated liver biopsies performed during clinical follow ups7. Another line of evidence is related to the observation that most patients with cryptogenic cirrhosis have the metabolic profile of patients with NASH and have a high recurrence of NASH post liver transplantation8. More recent data comes from placebo arms of clinical trials of NASH with sequential protocol biopsies, which provide a much more dynamic picture. In this context about 20-30% of patients with NAFLD will have NASH and of these 10-15% can progress to cirrhosis. Overall, histological worsening of liver damage is not a smooth transition from simple fatty liver to NASH and fibrosis, but rather the composite result of bouts of inflammation leading to fibrosis progression alternate to periods of regression. This pattern is particularly evident in placebo arms of randomized controlled trials (RCTs), where the primary endpoint of NASH regression w/o worsening of fibrosis or fibrosis regression w/o worsening of NASH can be attained by more than 20% of subjects9. The exact reasons for these fluctuating patterns of fibrosis progression and regressions are not completely understood, but it is likely that lifestyle changes play a major role.
Hepatic Complications of NAFLD
Severity of liver fibrosis is the main prognostic determinant in patients with NAFLD10. Compared to NAFLD patients with no fibrosis, NAFLD patients with fibrosis are at an increased risk for all-cause mortality, while the risk of liver-related mortality increases exponentially with each increase in the stage of fibrosis. For stage 1, mortality rate ratio was estimated at 1.41 (95% confidence interval (CI) 0.17-11.95); stage 2, 9.57 (95% CI 1.67-54.93); stage 3, 16.69 (95% CI 2.92-95.36); and stage 4 (cirrhosis), 42.30 (95% CI 3.51-510.34)10. A meta-analysis of early studies led to an estimation that progression of one fibrosis stage takes on average 14 years in patients with steatosis and 7 years in those with NASH11. However, fibrosis progression has a wide variability; a significant proportion of patients without histological NASH may rapidly progress, particularly those with visceral obesity, T2DM, older age, and Hispanic ethnicity. NASH without liver fibrosis does not seem to confer an increased risk of mortality, but it is likely associated with faster progression of liver fibrosis12, in keeping with a role of necroinflammatory changes in the development of fibrosis. Liver-specific mortality among those with NAFLD has also been reported to be 0.77 per 1,000-person years, but this rate is almost 10 times higher in patients who develop NASH with a reported rate of 11.77 per 1,000 person-years13,14. In patients with cirrhosis, liver disease becomes the leading cause of death. Furthermore, the risk of HCC related to NAFLD has increased substantially. In fact, the incidence of HCC among NAFLD patients is estimated to be 0.44 per 1,000 person-years15. Patients with NAFLD fibrosis stages 3 and 4 have almost a seven times higher risk of developing HCC compared to those without significant liver disease16. The presence of metabolic syndrome, especially obesity and T2DM, may hasten the development of HCC. The Surveillance, Epidemiology, and End Results Database (SEERD) study suggested that, although NAFLD was among the top three causes of HCC, those with NAFLD HCC incurred a higher mortality at one-year post-diagnosis due to a higher rate of diagnosis out of surveillance15. NAFLD/NASH is also rapidly becoming a major indication for liver transplantation in the United States. A recent analysis of the United States Scientific Registry of Transplant Recipients (SRTR) from 2012 to 2016 found that NASH was the fastest increasing indication for liver transplantation among those listed positioning NASH to become the most common cause for liver transplantation in the near future17. Another analysis of SRTR suggests that NASH-related is the fasting growing indication for HCC-listing for liver transplantation in the United States18. Given the lack of systematic screening or failure of screening for HCC in these individuals, it is possible that most cases of NASH-related HCC don’t get listed for liver transplantation or die while waiting for an organ16.
Prediction models for NAFLD in Asia and Europe forecast that, dependent on the rise of obesity and T2DM, there could be an up to 30% increase in total NAFLD cases between 2016-20305. Modelling shows slow growth in total cases and greater increase in advanced cases. 
NASH prevalence will increase 15–56%, while liver-related mortality and advanced liver disease will more than double. Within the European countries, Germany is expected to experience the highest increase in NASH and HCC cases while France is projected to have the most cases of compensated and decompensated cirrhosis by 2030. China is expected to have the highest increase in NAFLD cases, with an estimated 29% increase from 243.7 million in 2016 to 314.6 million in 2030. United States will experience the highest rate of decompensated cirrhosis with an estimated 56% increase from 17.3 million cases in 2016 to 27.0 million cases in 20305.
Extrahepatic complications in NAFLD 
Cardiovascular disease and extra-hepatic cancer predominate in subjects with lower fibrosis stages and NAFLD can also increase the risk of morbidity and mortality related to T2DM and to Cardiovascular Disease (CVD)6. A systematic review and a meta-analysis of 21 prospective, population-based studies in different ethnic groups, found that ultrasonography-diagnosed NAFLD and raised liver enzymes (alanine aminotransferase [ALT] and gammaglutamiltransferase [GGT]) were associated with an increased risk of incident T2DM19. In subjects with T2DM, the presence of NAFLD further increases the risk of incident CVD and the presence of T2DM complications20. NAFLD is associated with an increased prevalence of CVD, as well as incident non-fatal CVD events and CVD mortality. Among liver enzymes, GGT levels rather than ALT levels are most tightly associated with incidental CVD events, even when within the normal range. In a systematic review and a meta-analysis of 10 studies in different ethnic groups, 1 U/L higher GGT (on a log scale) was associated with a 20% increase in the risk CVD, a 54% increase in the risk of stroke, and a 34% increase in the risk of CVD and stroke combined21. In most cases, the association between NAFLD and CVD mortality was independent of classical CVD risk factor and, in a few cases, of the diagnosis of MS. In biopsy-proven NAFLD, the presence of hepatic fat accumulation was associated with increased carotid artery intima-media thickness and the presence of carotid plaques22, with significant carotid atherosclerosis occurring approximately 5-10 years earlier in subjects with NAFLD, independently of T2DM, and endothelial dysfunction. Cardiac involvement in NAFLD is not limited to coronary artery disease. Fatty liver is also associated with an increased intrapericardial and extrapericardial fat and a reduced phosphocreatine/adenosine triphosphate ratio, a recognized in vivo marker of myocardial energy metabolism, even in subjects without risk factors for cardiovascular diasease23. Subjects with high liver fat have lower insulin-stimulated myocardial glucose uptake and lower coronary flow reserve compared with the low liver fat group24, suggesting that liver fat content is an independent indicator of myocardial insulin resistance and reduced coronary functional capacity. 
Environmental and genetic risk factors for disease progression
The severity of the metabolic abnormalities, insulin resistance, and in particular the presence of T2DM, represent the major risk factor associated with development of advanced liver disease, and with fibrosis progression in prospective studies in patients with NAFLD1 (Figure 1). Variations in body weight and associated metabolic abnormalities represent the main clinical predictor of the liver disease evolution during the follow-up. A key mediator of liver disease progression induced by metabolic risk factors may be represented by severity of hepatic fat accumulation, which has been linked with short and long term fibrosis progression independently of several confounders25. Industrial fructose intake has been associated with higher risk of both development and progression of NAFLD, probably by stimulating de novo lipogenesis26, and an increase in the ratio of dietary saturated/unsaturated fat intake may also play a role. On the other hand, the role of red meat consumption is less established. 
Accumulating evidence indicate that hepatic fat and NAFLD are strongly heritable conditions27. Multi-ethnic cohort studies demonstrated that there is a strong interethnic variability in the susceptibility towards NAFLD development, being higher in Hispanics, intermediate in Europeans and lower in African-Americans, independently of adiposity, T2DM, and socioeconomic factors. The risk of progressive NAFLD is higher in first-degree relatives of patients with NAFLD cirrhosis as compared to the general population, independently of several confounders. The most important common genetic determinants of hepatic fat variability and the susceptibility to develop NAFLD has been uncovered thanks to the advent of genomewide association studies in the last years. The major one is the rs738409 C>G encoding for the I148M protein variant of Patatin-like phospholipase domain-containing 3 (PNPLA3), accounting for a large fraction of the increased risk of this condition in Hispanics. The I148M variant increases susceptibility to the whole spectrum of liver damage related to NAFLD, from simple steatosis, to NASH, fibrosis, and cirrhosis, thereby representing a general modifier of liver disease progression. Furthermore, the I148M variant heightens the risk of progression to hepatocellular carcinoma development independently of the effect on fibrosis. In Europeans, homozygosity for the mutation is enriched almost nine-fold in patients who develop NAFLD-HCC as compared to the general population, while absence of the variant can rule out HCC risk with a high specificity in the general population27. Carriage of this variant impacts on the risk of liver disease particularly during the developmental age interacting with dietary factors such as intake of fructose enriched drinks, and lack of physical activity28. Other common genetic mutations regulating hepatocellular lipid handling contribute to the risk of NAFLD. The rs58542926 C>T encoding for the E167K variant in Transmembrane 6 superfamily member 2 (TM6SF2) favours hepatic fat accumulation by decreasing lipid secretion in very low-density lipoproteins (VLDL), also leading to increased susceptibility to liver damage. At the same time, this genetic factor protects from cardiovascular disease by reducing circulating lipids27. Variants in Glucokinase regulator (GCKR) and in Membrane bound O-acyl transferase 7 (MBOAT7) also contribute to the risk, by increasing de novo lipogenesis and altering the remodelling of phospholipids, respectively. All these factors result in fat accumulation and higher risk of liver disease27.   Conversely, the most recent HSD17B13 variant T>TA confers protection from liver damage in NAFLD29. The impact of the genetic variants on hepatic fat content, the risk of NAFLD and that of cirrhosis increases exponentially with increasing body mass index (BMI), indicating the presence of a synergism between these components of the disease. Importantly, in individuals at high genetic risk a healthy dietary patter modelled on the Mediterranean diet as well as regular physical activity may reduce the risk of NAFLD30.
Conclusions
NAFLD is not a benign disease as it can progress to advanced liver disease, hepatocellular carcinoma, liver transplantation, and death. The prevalence and incidence of NAFLD is growing globally. Though the number of patients who actually progress is small, on a global level the burden is substantial. Continuous study is needed to develop interventions to reverse the course of NAFLD especially as our understanding of NAFLD evolves.   
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Figure 1. Environmental and genetic factors implied in the development of NAFLD, according to different ages of life. 

	NAFLD can progress to advanced liver disease, hepatocellular carcinoma, liver transplantation and death
	NAFLD is associated with an increased mortality rate, with the three top causes of death being cardiovascular disease, extra-hepatic cancer and liver disease
	Prediction models for NAFLD forecast a 30% increase in total NAFLD cases in the next decade
	Worsening of liver damage depends on both environmental and genetic factors, with fluctuant phases of fibrosis progression and regression
	Advanced fibrosis bears a seven times higher risk for developing hepatocellular carcinoma, which has become the fastest growing indication for liver transplantation in the United States



